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Expression of X-linked Inhibitor of Apoptosis Protein  
in Neoplastic Thyroid Disorder
X-linked inhibitor of apoptosis protein (XIAP) is associated with tumor genesis, growth, 
progression and metastasis, and acts by blocking caspase-mediated apoptosis. In the 
present study, we sought to evaluate the expression patterns of XIAP in various neoplastic 
thyroid disorders and determine the association between XIAP expression and 
clinicopathologic factors. Expression of XIAP was evaluated with immunohistochemical 
staining using monoclonal anti-XIAP in 164 specimens of conventional papillary thyroid 
carcinoma (PTC) and 53 specimens of other malignant or benign thyroid tumors. XIAP 
positivity was observed in 128 (78%) of the 164 conventional PTC specimens. Positive rates 
of XIAP expression in follicular variant PTC, follicular, medullary, poorly differentiated, and 
anaplastic thyroid carcinoma specimens were 20%, 25%, 38%, 67%, and 38%, 
respectively. Six nodular hyperplasia specimens were negative and 1 of 7 follicular 
adenomas (8%) was positive for XIAP. Lateral neck lymph node metastases were more 
frequent in patients negative for XIAP expression (P = 0.01). Immunohistochemical 
staining for XIAP as a novel molecular marker may thus be helpful in the differential 
diagnosis of thyroid cancer. Moreover, high XIAP expression in conventional PTC is strongly 
associated with reduced risk of lateral neck lymph node metastasis.
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INTRODUCTION
X-linked inhibitor of apoptosis protein (XIAP) is a member of 
the Inhibitor of Apoptosis (IAP) protein family that selectively 
binds and inhibits caspases-3, -7, and -9. XIAP blocks the down-
stream portion of the apoptosis pathway and inhibits cell death 
in response to multiple stimuli (1-3). All cells have a finite life-
span, and cell death occurs mainly as a result of passive necrotic 
processes and/or active apoptosis (programmed cell death) (4, 5). 
Apoptosis is the most common mechanism by which the body 
eliminates damaged or unnecessary cells without local inflam-
mation from leakage of cell contents (6, 7). This process relies 
on a tightly balanced signaling pathway involving both pro- and 
anti-apoptotic proteins. Defective apoptosis represents a major 
causative factor in the development and progression of cancer 
(8). The IAP protein family plays critical roles in maintaining tight 
apoptogenic regularities.
  XIAP expression is increased in a number of human malig-
nancies, including colorectal, esophageal, ovarian, renal cell, 
hepatocellular, and prostate cancer (2). Several reports have con-
firmed higher XIAP expression in thyroid cancer, compared to 
benign thyroid disorder (9). Moreover, a recent study showed 
the utility of XIAP expression as a marker to predict the aggres-
siveness of papillary thyroid carcinoma (PTC) (10). 
  In the present study, we evaluated the expression patterns of 
XIAP in various neoplastic thyroid disorders. We additionally 
aimed to delineate possible associations between XIAP expres-
sion and clinicopathologic parameters in conventional PTCs, 
the most common type of thyroid cancer.
MATERIALS AND METHODS
Thyroid samples 
We analyzed 217 formalin-fixed, paraffin-embedded thyroid tis-
sue specimens obtained with thyroidectomy at the Asan Medi-
cal Center between 1996 and 2003. The study specimens com-
prised 164 conventional PTCs and 40 other malignant thyroid 
tumors, including 10 follicular variant PTCs, 8 follicular thyroid 
carcinomas (FTC), 8 medullary thyroid carcinomas, 8 poorly dif-
ferentiated thyroid carcinomas and 8 anaplastic thyroid carci-
nomas. The remaining 13 specimens were benign thyroid tu-
mors, including 6 nodular hyperplasia and 7 follicular thyroid 
adenomas. 
  All thyroid specimens were stained using hematoxylin and 
eosin, and reviewed by two pathologists. Diagnosis was con-
firmed according to the World Health Organization histologic Yim JH, et al.  •  XIAP in Thyroid Disorder
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classification of thyroid tumors. 
Immunohistochemical analysis of XIAP 
Sections of formalin-fixed, paraffin-embedded tumor tissue 
specimens were deparaffinized, treated with 3% hydrogen per-
oxide to block endogenous peroxidase activity, and microwaved 
in 0.01 M/L citric acid (pH 6.0) for 6 min at 100°C, followed by 
slow cooling for antigen retrieval. Slides were incubated for 72 hr 
at 4°C with a monoclonal anti-XIAP antibody (BD Biosciences, 
Franklin Lakes, NJ, USA), stained using Envision-Plus reagents 
(DAKO, Carpinteria, CA, USA) and diaminobenzidine as chro-
mogen, and counterstained with hematoxylin.
  The extent of staining was graded semiquantitatively as fol-
lows: no foci (0), rare-few foci (1+), multiple foci (2+), and re-
gional-diffuse staining (3+). Staining intensity was graded semi-
quantitatively as follows: negative (0), weak (1+), moderate (2+), 
and strong (3+). Specimens were classified as XIAP-positive when 
the sum of the extent score plus intensity score was equal to more 
than 4 points (Fig. 1). 
Clinicopathologic features of conventional papillary 
thyroid carcinoma
Patients diagnosed with conventional PTC and subjected to thy-
roid surgery at Asan Medical Center between 1996 and 1998 were 
retrospectively analyzed. Demographic data, including age and 
gender, and pathologic data, such as tumor size, multifocality, 
extrathyroidal invasion and AJCC TNM 2002 staging, were re-
viewed.
Statistics 
Categorical variables are presented as numbers and percentag-
es, and continuous variables as means ± standard deviations or 
median values with a range. Comparison of clinicopathologic 
parameters according to positivity of XIAP expression was per-
formed using the Student’s t test for continuous data and Fish-
er’s exact test for categorical data. All P values were two-sided. 
Data were considered statistically significant at P < 0.05. R ver-
sion 2.11.1 and R libraries car and Cairo were used to analyze 
data (R Foundation for Statistical Computing, Vienna, Austria, 
http://www.R-project.org) (11).  
Ethics statement
Formalin-fixed, paraffin-embedded tumor specimens were ob-
tained from the hospital research material pool after approval 
from the institutional review board of the Asan Medical Center 
(2010-0477). Informed consent was exempted by the board.
 
RESULTS
XIAP expression in malignant and benign thyroid tumors 
Among the 164 conventional PTC specimens, 128 (78%) stained 
positive for XIAP (Table 1). In terms of staining extent, 130 (82%) 
specimens scored 2+ or 3+. Intensity scores of 1+, 2+, and 3+ were 
conferred to 31 (19%), 81 (49%), and 27 (16%) specimens, respec-
tively.
  Positive XIAP staining was found in 2 (20%) of 10 follicular 
variant PTCs, 2 (25%) of 8 FTC, 3 (38%) of 8 medullary thyroid 
carcinomas, 4 (67%) of 6 poorly differentiated thyroid carcino-
mas, and 3 (38%) of 8 anaplastic thyroid carcinomas.
  Among the benign thyroid nodule specimens, none of the 6 
nodular hyperplasias and only one of 7 (14%) follicular thyroid 
adenomas displayed XIAP-positive staining.  
Clinicopathological factors of classic PTC according to 
positivity for XIAP expression 
Among the 128 patients in the XIAP-positive group, 35 (27%) were 
in the N0 stage, 80 (63%) in the N1a stage and 11 in the N1b stage 
(Table 2). Among the 34 patients in the XIAP-negative group, 5 
A C B
Fig. 1. XIAP expression in PTC specimens. (A) Weak-rare foci positive XIAP staining; (B) Moderate multifocal positive XIAP staining; (C) Strong diffuse positive XIAP staining. Yim JH, et al.  •  XIAP in Thyroid Disorder
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(14%) patients were in the N0 stage, 20 (56%) in the N1a stage 
and 11 (33%) in the N1b stage. The incidence of metastasis to 
lateral neck lymph node was higher in patients with negative 
XIAP expression than those positive for XIAP (P = 0.01). 
  No significant differences in age, sex, tumor diameter, multi-
focality, lymphovascular invasion, extrathyroidal extension, 
lymph node metastasis, and AJCC TNM 2002 stage were ob-
served between the two groups. 
DISCUSSION
The major histologic thyroid cancer types are composed of dif-
ferentiated thyroid carcinomas, such as PTC and FTC, and un-
differentiated thyroid carcinomas, such as medullary thyroid 
cancer or anaplastic thyroid cancer. PTC is the predominant thy-
roid cancer type in most parts of the world. Thyroid fine-needle 
aspiration cytology (FNAC) is a standard diagnostic tool for thy-
roid neoplasms (12). However, diagnostic challenges of inade-
quate specimens and indeterminate cytology categories that fail 
to meet the criteria for definitive diagnosis of cancer present sig-
nificant obstacles to clinicians (13, 14). Data from the present 
study support the potential of XIAP as a molecular marker in 
thyroid cancer diagnosis. 
  More recently, molecular diagnoses, such as galectin-3, HBME-
1, cytokeratin-19 or B-type raf (BRAF) gene mutations have been 
introduced, but their clinical value is yet to be established (15-
17). Some groups have shown that immunohistochemical test-
ing for a combination of 2 or more markers improves the accu-
racy of diagnosis (18-21). In our experiments, most specimens 
with benign pathology stained negative for XIAP. Thus, XIAP im-
munostaining from FNAC specimens, in combination with oth-
er potential markers, may be promising for the differential diag-
nosis of thyroid neoplastic disorders.
  The incidence of positive XIAP expression was higher overall 
in thyroid cancer, particularly in cases of conventional PTC, com-
pared with benign thyroid nodules. These findings are consis-
tent with other studies suggesting that XIAP contributes to tumor 
cell survival as an apoptosis inhibitor (2). However, XIAP immu-
nostaining is inappropriate to differentiate between other his-
tologic types of thyroid cancer and benign nodules. In particu-
lar, FTC and follicular adenoma, which are difficult to diagnose 
using cytology, showed similar patterns of XIAP expression in 
this study. However, the number of FTC and follicular adenoma 
samples analyzed was limited, and thus, a follow-up study on a 
Table 1. Summary of XIAP immunostaining results for thyroid neoplasms and disorders
Diagnosis
Malignancy Benign
Papillary carcinoma
Follicular 
carcinoma
Medullary 
carcinoma
Poorly differ-
entiated  
carcinoma
Anaplastic 
carcinoma Total Nodular  
hyperplasia
Follicular  
adenoma Total
conventional Follicular 
variant
Number 164 10 8 8 6 8 204 6 7 13
No staining   25 (15) 5 (50) 6 (75) 4 (50) 2 (33) 5 (63)    47(23) 6 (100) 6 (86) 12 (92)
Extent score
   1+
   2+
   3+
 
  4 (2)
  23 (17)
107 (65)
 
2 (22)
1 (11)
2 (11)
 
0
0
2 (25)
 
2 (25)
1 (13)
1 (13)
 
0
2 (33)
2 (33)
 
0
0
4 (38)
 
  6 (3)
  27 (13)
118 (58)
 
0
0
0
 
0
1 (8)
0
 
0
1 (4)
0
Intensity score
   1+
   2+
   3+
 
  31 (19)
  81 (49)
  27 (16)
 
0
3 (30)
2 (20)
 
0
1 (13)
1 (13)
 
1 (13)
1 (13)
2 (25)
  
1 (17)
1 (17)
2 (33)
 
3 (25)
1 (13)
0
 
  36 (18)
  88 (43)
  34 (17)
 
0
0
0
 
0
0
1 (14)
 
0
0
1 (8)
XIAP positive (sum of extent score and intensity score equal or more than 4)
   Positive                        128 (78)          2 (20)            2 (25)            3 (38)
   Negative                         36 (22)          8 (80)            6 (75)            5 (63)
4 (67)
2 (33)
3 (38)
5 (63)
142 (70)
  62 (30)
0
6 (100)
1 (14)
6 (86)
1 (8)
12 (92)
Numbers in parentheses are percentages. The extent of staining was graded semiquantitatively as follows: no foci (0), rare-few foci (1+), multiple foci (2+), and regional-diffuse 
staining (3+). The intensity of staining was graded semiquantitatively as follows: negative (0), weak (1+), moderate (2+), and strong (3+). XIAP, X-linked inhibitor of apoptosis 
protein.
Table 2. Clinicopathological features of conventional-type papillary thyroid carcinoma 
according to XIAP expression
Parameters
Total  
(n = 164)
XIAP (-) 
(n = 36)
XIAP (+)  
(n = 128) P value
Age (yr) 44 ± 13 45 ± 12 43 ± 13 0.54
Gender, male   28 (17)   8 (22) 20 (16) 0.45
Tumor diameter (cm) 2.5 ± 1.5 2.1 ± 1.3 2.6 ± 1.6 0.08
Multifocal tumor   76 (46) 17 (47) 59 (46) 1.00
Lymphovascular invasion 10 (6) 3 (8) 7 (5) 0.46
Extrathyroidal invasion 102 (62) 22 (61) 80 (63) 1.00
N stage
   N0
   N1a
   N1b
 
  40 (24)
100 (61)
  24 (15)
 
  5 (14)
20 (56)
11 (31)
 
35 (27)
80 (63)
13 (10)
0.01
AJCC TNM staging
   I/II
   III/IV
 
  96 (59)
  68 (41)
 
21 (58)
15 (42)
 
75 (59)
53 (41)
1.00
Numbers in parentheses are percentages. N1a, cervical lymph node (LN) metastasis 
at level VI (i.e., pretracheal, paratracheal, prelaryngeal/Delphian LN); N1b, cervical LN 
metastasis defined as unilateral, bilateral or contralateral cervical or superior medias-
tinal LNs, classified based on AJCC/UICC TNM staging; AJCC/UICC TNM, American 
Joint Committee on Cancer/International Union against Cancer Tumor-Node-Metasta-
ses classification. XIAP, X-linked inhibitor of apoptosis protein.Yim JH, et al.  •  XIAP in Thyroid Disorder
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larger scale is needed to evaluate the diagnostic value of XIAP 
expression in these diseases.
  Interestingly, follicular variant PTCs, such as FTC, showed a 
lower incidence of positive XIAP expression than conventional 
PTC. Although PTC as a group constitutes tumors with favor-
able biologic behavior that share characteristic microscopic fea-
tures, increasing evidence suggests that they represent a hetero-
geneous group of tumors, and specific genetic alterations influ-
ence histologic variants and tumor behavior (22). Adeniran et 
al. (23) reported that the molecular profile of the follicular vari-
ant PTC is close to that of FTC, with high prevalence of RAS and 
a very low BRAF mutation rate. Riveral et al. (24) reported that 
the mutational patterns of encapsulated follicular variant PTC 
and FTC are similar. Infiltrative follicular variant PTC displays a 
BRAF and RAS genotype in between FTC and conventional PTC. 
Encapsulated follicular variant PTC has behavioral profile simi-
lar to that of FTC, while infiltrative follicular variant PTC has an 
invasive and behavioral profile similar to that of conventional 
PTC. XIAP appears to be associated with histologic variant and 
clinical behavior, similar to BRAF and RAS.  
  We further evaluated the potential association between XIAP 
expression and clinicopathological factors in patients with con-
ventional PTC. XIAP expression was negatively associated with 
risk of lateral neck lymph node metastasis in our study. This re-
sult was inconsistent with a recent report from China (10). In 
the earlier study, XIAP expression was positively associated with 
the presence of lymph node metastasis in PTC. Several Korean 
groups have shown a high prevalence of the BRAF V600E muta-
tion (around 70%-80%) in Korea (15-17), compared with other 
parts of the world. Additionally, Gu et al. (25) detected the BRAF 
V600E mutation in 34.1% of classical PTC samples. This region-
al difference in the prevalence of the BRAF mutation in PTC be-
tween Korea and China could explain the discrepancy regard-
ing the association of XIAP with neck node metastasis. Further 
studies are required to explore the potential interactions be-
tween BRAF and XIAP. 
  Moreover, controversial results have been reported with re-
gard to the association of XIAP expression with clinical outcomes 
in various cancer types other than thyroid cancer. A number of 
studies have shown that increased XIAP is correlated with de-
creased survival in acute myeloid leukemia, diffuse large B-cell 
lymphoma, and renal cell carcinoma (26). In another study, high 
levels of XIAP were correlated with favorable outcomes in pros-
tate cancer and early-stage non-small cell lung cancer (27). In 
the current investigation, XIAP expression was negatively asso-
ciated with risk of lateral neck lymph node metastasis. Lateral 
neck lymph node metastasis is one of the important prognostic 
factors for recurrence and disease-specific mortality in thyroid 
cancer patients (28). Eventually, XIAP expression may be used 
as a surrogate marker to predict prognosis in thyroid cancer.
  The possible mechanisms linking XIAP expression to clinical 
outcomes have been explored. The anti-apoptotic activity of 
XIAP is regulated by Smac/DIABLO. This protein is normally 
localized to mitochondria and released into the cytosol during 
the early stages of apoptosis, where it promotes caspase activity 
by inhibiting XIAP. Recent studies have reported that the relative 
proportion of XIAP, compared with Smac/DIABLO, rather than 
absolute value of XIAP expression, may determine tumor cell 
survival (27, 29, 30). However, the present investigation focused 
solely on XIAP expression, and follow-up studies are required 
to establish the roles of XIAP and Smac/DIABLO in tumorigen-
esis and metastasis of thyroid cancer. 
  In conclusion, immunohistochemical staining for XIAP as a 
potential novel molecular marker may aid in differential diag-
nosis of thyroid cancer. Furthermore, high XIAP expression in 
conventional PTC is strongly associated with reduced risk of lat-
eral neck lymph node metastasis.
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